AI Article Synopsis

  • Complete human factor VIII DNA clones have been expressed in baby hamster kidney cells, allowing for the purification and analysis of recombinant factor VIII (rVIII) compared to plasma-derived factor VIII (pdVIII).
  • Both rVIII and pdVIII show similar polypeptide patterns and Western blot recognition, indicating they share structural characteristics, including multiple polypeptides ranging from 80,000 to 210,000 in molecular weight.
  • Functional similarities were observed, as rVIII undergoes activation and processing by thrombin and other factors in the same way as pdVIII, suggesting that rVIII and pdVIII have comparable structural and functional properties.

Article Abstract

Recently, complete human factor VIII DNA clones have been obtained and subsequently expressed in baby hamster kidney cells (Wood, W. I., Capon, D. J., Simonsen, C. C., Eaton, D. L., Gitschier, J., Keyt, B., Seeburg, P. H., Smith, D. H., Hollingshead, P., Wion, K. L., Delwart, E., Tuddenham, E. G. D., Vehar, G. A., and Lawn, R. M. (1984) Nature 312, 330-337). The recombinant factor VIII (rVIII) protein secreted from these cells has now been purified allowing its structural analysis and comparison to plasma-derived factor VIII (pdVIII). Analysis of purified rVIII by sodium dodecyl sulfate-polyacrylamide gel electrophoresis shows that it consists of multiple polypeptides with relative mobilities (Mr) ranging from 80,000-210,000. The same pattern of polypeptides is also observed for pdVIII resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The proteins associated with rVIII are recognized by pdVIII antibodies in a Western blot. When rVIII and pdVIII are subjected to isoelectric focusing they are resolved into a similar pattern of protein bands. Thrombin, factor Xa, and activated protein C, which modulate factor VIII activity by proteolysis, process rVIII in the same manner they do pdVIII. As is the case for pdVIII, thrombin activation of rVIII coagulant activity correlates with the generation of subunits with Mr of 73,000, 50,000 and 43,000. These subunits appear to form a metal-(perhaps Ca2+) linked complex. EDTA inactivates thrombin-activated rVIII and pdVIII, with the activity being regenerated after the addition of a molar excess of MnCl2. The results suggest that rVIII is structurally and functionally very similar to pdVIII.

Download full-text PDF

Source

Publication Analysis

Top Keywords

factor viii
20
human factor
8
rviii
8
pdviii
8
sodium dodecyl
8
dodecyl sulfate-polyacrylamide
8
sulfate-polyacrylamide gel
8
gel electrophoresis
8
rviii pdviii
8
factor
6

Similar Publications

Adeno-associated virus (AAV)-associated gene therapy has been increasingly promising, in light of the drugs progressed to clinical trials or approved for medications internationally. Therefore, scalable and efficient production of recombinant AAV is pivotal for advancing gene therapy. Traditional methods, such as the triple-plasmid transfection of human embryonic kidney 293 cells in suspension culture, have been widely employed but often hampered by low unit yield.

View Article and Find Full Text PDF

Limited data are available on VWF activity (VWF:Act) and factor VIII (FVIII:C) levels during delivery after VWF/FVIII concentrate administration in women with von Willebrand disease (VWD). We aimed to evaluate treatment with a specific VWF/FVIII concentrate on factor levels in women with VWD during delivery and the postpartum period. A retrospective single-center study was conducted between January 1, 2008, and August 1, 2022.

View Article and Find Full Text PDF

Background: Rare bleeding disorders (RBDs) include fibrinogen (Factor I), prothrombin (Factor II), Factor V(FV), combined Factor V and Factor VIII, Factor VII, Factor X, Factor XI, Factor XII, and Factor XIII deficiencies. This group accounts for 3-5% of all factor deficiencies. Different symptoms may occur, ranging from mild or moderate bleeding to serious and life-threatening bleeding, which may not be related to the factor level.

View Article and Find Full Text PDF

Background And Aims: We assessed clinical, procoagulant and genetic risk factors and clinical outcomes in dabigatran-treated patients with non-tumoural acute and acute-on-chronic portal vein thrombosis (PVT).

Methods: Patients with a new diagnosis of non-tumoural acute and acute-on-chronic PVT between January 2021 and January 2024 (aged ≥ 18 years) in those without/with cirrhosis (Child-Pugh (CP)-A/B/C ≤ 10) were started on dabigatran and followed and compared with those on vitamin K antagonist (VKA) and untreated individuals.

Results: Dabigatran was prescribed in 119 patients with PVT type 1 (61, 51.

View Article and Find Full Text PDF

Silent myocardial infarction (SMI) is a type of myocardial infarction that occurs in the absence of, or with, minimal symptoms, often leading to a delay in medical treatment. There is a lack of data regarding the incidence and/or prevalence of a left ventricular (LV) thrombus in those who have had an SMI, due to the rarity of such cases. We describe a case of an SMI with LV thrombus in an otherwise healthy young man, whose first presentation was with stroke-type symptoms and who was also later found to have a Factor V Leiden (FVL) mutation and raised factor VIII levels.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!